The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

• Autors principals: Joshua Burshtein (Autor), Milaan Shah (Autor), Danny Zakria (Autor), Benjamin Lockshin (Autor), Jeff Crowley (Autor), Joseph F. Merola (Autor), Ken Gordon (Autor), Mona Shahriari (Autor), Neil J. Korman (Autor), Raj Chovatiya (Autor), Robert Kalb (Autor), Mark Lebwohl (Autor)
• Format: Llibre
• Publicat: Adis, Springer Healthcare, 2024-02-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract Introduction Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F and has demonstrated efficacy for trea...